GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » Beta

Qualigen Therapeutics (FRA:7R90) Beta : 0.66 (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), Qualigen Therapeutics's Beta is 0.66.


Qualigen Therapeutics Beta Historical Data

The historical data trend for Qualigen Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Beta Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
Beta
- - - -0.58

Qualigen Therapeutics Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.58 -0.48 -0.49 0.09

Competitive Comparison of Qualigen Therapeutics's Beta

For the Biotechnology subindustry, Qualigen Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualigen Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Beta falls into.



Qualigen Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Qualigen Therapeutics  (FRA:7R90) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Qualigen Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics Business Description

Traded in Other Exchanges
Address
5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines